Rapid progress toward the clinic

We are using our proprietary TANGO platform to build a pipeline of potential new medicines to help people with severe genetic epilepsies and other diseases that are caused by an individual gene. Stoke’s lead program is a potentially disease-modifying treatment for Dravet syndrome, a severe and progressive form of genetic epilepsy. Beyond genetic epilepsies, we are advancing several other early programs, including haploinsufficiencient diseases of the CNS, eye, kidney and liver.